MavenView Uses AI to Analyze Emerging Technologies
In today’s environment, as scientists and entire industries are working to discover cures and therapies for rare and orphan diseases, knowing who to partner with and where the relevant research is happening is all-important and time-critical to the mission.
Business leaders in biotechnology seek to speed discovery and commercialization through collaboration, partnerships, and acquisitions while staying abreast of the competition. They invest in squads of highly trained expert data analysts who continually sift through multiple databases to connect the dots.
The process is costly, inefficient, and often yields incomplete or inaccurate results. Users get lost in the data, and one misspelling or letter typed wrong can send a query down the rabbit hole. MavenView, a Columbus-based data analytics company, has a solution to this problem, which heretofore has seemed unsolvable.
“We have a big data search mechanism that meets a particular unmet need around rare diseases,” said Nicole Weidner, CEO. “We connect rare diseases with the associated genes, patient populations, pre-clinical and clinical studies, therapeutics, and the researchers and organizations involved. We are talking about searching through more than 100 million records.”
Matching Researchers and Commercial Partners
MavenView’s advanced search engine and machine learning platform integrate disparate databases, making the “who and where” information instantaneously searchable and actionable. The platform normalizes the data from public and proprietary databases and puts it in one spot, accessible with an easy-to-phrase query and the click of a mouse. The company is focusing on the rare disease space initially, with the intent of building out modules to serve other verticals over time.
A significant aspect of the MavenView platform is that it doesn’t require someone to have a Ph.D. in molecular biology or genetics to perform searches and extract granular and specific data.
“A user doesn’t have to type in a hundred lines of a search query or spell every medical term or chemical name correctly,” Weidner said, “We have done that work in the background for them by building vocabularies that do the semantic searching. For example, a user might want to ask if someone somewhere has done pre-clinical work on a particular rare disease, and our product serves up all the aliases for the disease, as well as related diseases and genes that have published studies.
MavenView can integrate private data into its platform while keeping it secure. Organizations like the Department of Defense (DoD) or research organizations could leverage MavenView capabilities to clean and incorporate their own research data to scout for technology partners and competitors.
MavenView Reveals Landscapes of Scientists, Decision-makers, and Thought Leaders
MavenView delivers a landscaped map of connections between scientists, organizations, patents, publications, and clinical trials. Results are accurate and virtually instantaneous. Landscaping intellectual property, finding the names of experts and organizations studying emerging technologies, or bench-marking competition and funding activity, are the types of information MavenView assembles.
The platform has applicability in many segments, providing the type of information that feeds into technology or patent acquisitions and M&A evaluations or equips a company to pivot to entirely new lines of business when market conditions deteriorate or open new windows of opportunity.
MavenView provides a rate of change view over a particular technology allowing organizations to assess whether they are moving ahead or falling behind relative to competitors. The platform makes data more usable and functional, helps eliminate the costs associated with multiple database subscriptions, improves accuracy, and helps highly skilled data analysts become more efficient.